{"id":53310,"date":"2023-09-20T09:44:53","date_gmt":"2023-09-20T09:44:53","guid":{"rendered":"https:\/\/medsname.com\/honvan\/"},"modified":"2026-04-30T16:30:24","modified_gmt":"2026-04-30T16:30:24","slug":"honvan","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/honvan\/","title":{"rendered":"Honvan"},"content":{"rendered":"<div class=\"medsbase-tldr-answer\" style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:14px 18px;margin:18px 0;border-radius:4px;\">\n<h3 style=\"margin-top:0;\">R\u0103spuns rapid<\/h3>\n<p style=\"margin-bottom:0;\"><strong>Honvan<\/strong> \u2014 Fosfestrol Tetrasodiu 120 mg (Asta Medica). Difosfat de dietilstilbestrol \u2014 estrogen de doz\u0103 mare pentru cancerul de prostat\u0103 metastatic avansat. \u00cenlocuit \u00een mare parte cu agonii LHRH; r\u0103m\u00e2ne \u00een utilizare \u00een medii cu resurse limitate sau \u00een set\u0103ri paliative.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f7f7f7;border-left:4px solid #2c7cb0;padding:14px 18px;margin:18px 0;border-radius:4px;\">\n<p style=\"margin:0 0 6px 0;\"><strong>Ce beneficii ofer\u0103 MedsBase:<\/strong><\/p>\n<ul style=\"margin:6px 0 0 22px;padding:0;list-style:disc;\">\n<li>produc\u0103tor certificat WHO-GMP<\/li>\n<li>Ambalaj discret \u00een plic simplu<\/li>\n<li>Livrare \u00een toat\u0103 lumea<\/li>\n<li>Evaluat de peste 1.400 de clien\u021bi (<a href=\"https:\/\/medsbase.com\/ro\/reviews\/\">cite\u0219te recenziile<\/a>)<\/li>\n<\/ul>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"background:#eef7ee;border-left:4px solid #4caf50;padding:10px 14px;margin:14px 0;border-radius:3px;\">\ud83d\udce6 <strong>Garan\u021bia de retransmitere:<\/strong> dac\u0103 comanda dvs. nu a ajuns \u00een 20 de zile lucr\u0103toare de la expediere, o retransmitem f\u0103r\u0103 costuri suplimentare. <a href=\"https:\/\/medsbase.com\/ro\/medsbase-re-shipment-assurance-policy\/\">Cite\u0219te politica<\/a>.<\/p>\n<h3>De ce s\u0103 comanzi de la MedsBase<\/h3>\n<p>Honvan este expediat de la un produc\u0103tor certificat WHO-GMP \u00een ambalaj neutru, facturat printr-un procesor de plat\u0103 reglementat (descrierea extrasului de cont indic\u0103 un procesor de plat\u0103 cu card reglementat \u2014 niciodat\u0103 MedsBase sau nume de medicament). Fiecare comand\u0103 beneficiaz\u0103 de Garan\u021bia noastr\u0103 de Reshipment pe 20 de zile lucr\u0103toare.<\/p>\n<div class=\"medsbase-specialist-strip\" style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:14px 18px;margin:18px 0;border-radius:4px;\">\n<p style=\"margin:0;\"><strong>\u26a0\ufe0f Terapie oncologic\u0103 supravegheat\u0103 de specialist<\/strong> \u2014 acest medicament este ini\u021biat, monitorizat \u0219i \u00eentrerupt de un oncolog sau hematolog. Dozarea depinde de tipul tumorii, stadiul, suprafa\u021ba corporal\u0103, func\u021bia organelor \u0219i terapia concomitant\u0103. Autotratamentul nu este adecvat; informa\u021biile de mai jos au scop educa\u021bional \u0219i sus\u021bin conversa\u021biile informate cu specialistul dumneavoastr\u0103.<\/p>\n<\/div>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:12px 16px;margin:14px 0;border-radius:3px;\"><strong>Risc cardiovascular sever<\/strong><br \/>Fosfestrol prezint\u0103 risc cardiovascular substan\u021bial \u2014 TVP, EP, IM, AVC, reten\u021bie de lichide. Utiliza\u021bi doar atunci c\u00e2nd alternativele moderne (agoni LHRH, abirateron\u0103, enzalutamid\u0103) nu sunt disponibile sau potrivite. Discu\u021bie obligatorie despre trombo-profilaxie cu cardiologul.<\/div>\n<h2 id=\"faqs\">\u00centreb\u0103ri frecvente<\/h2>\n<h3>C\u00e2nd se utilizeaz\u0103?<\/h3>\n<p>Difosfat de dietilstilbestrol \u2014 estrogen de doz\u0103 mare pentru cancerul de prostat\u0103 metastatic avansat. \u00cenlocuit \u00een mare parte cu agonii LHRH; r\u0103m\u00e2ne \u00een utilizare \u00een medii cu resurse limitate sau \u00een set\u0103ri paliative.<\/p>\n<h3>Efecte secundare de monitorizat?<\/h3>\n<p>V\u0103rs\u0103turi de c\u0103ldur\u0103, ginecomastie, oboseal\u0103, disfunc\u021bie sexual\u0103 (efect de clas\u0103 antiandrogen). Monitorizare specific\u0103 medicamentului conform indica\u021biilor din casetele de siguran\u021b\u0103 de mai sus.<\/p>\n<h3>Interac\u021biuni medicamentoase?<\/h3>\n<p>Variaz\u0103 \u00een func\u021bie de molecul\u0103 \u2014 abirateronul este substrat CYP3A4; bicalutamida este substrat CYP3A4. Dezv\u0103lui\u021bi \u00eentotdeauna toate medicamentele. Inhibitorii\/induc\u0103torii puternici ai CYP3A4 afecteaz\u0103 semnificativ nivelurile.<\/p>\n<h3>C\u00e2nd ar trebui oprit?<\/h3>\n<p>La progresia bolii, toxicitate intolerabil\u0103 sau r\u0103spuns succesiv cu pauz\u0103 planificat\u0103 a tratamentului. \u00centotdeauna decis de specialist \u2014 \u00eentreruperea brusc\u0103 poate duce la cre\u0219tere tranzitorie a PSA (r\u0103spuns de sevraj) care nu este \u00een general \u00eengrijor\u0103toare.<\/p>\n<h3>Monitorizare PSA?<\/h3>\n<p>PSA la fiecare 1-3 luni \u00een timpul terapiei. Cre\u0219terea PSA sub castrare sugereaz\u0103 rezisten\u021b\u0103 la castrare \u2014 poate fi necesar\u0103 trecerea la agen\u021bi de linia a doua (abirateron, enzalutamid, docetaxel).<\/p>\n<h3>Blocaj androgen combinat?<\/h3>\n<p>Agonist LHRH (goserelin, leuprolid\u0103) + bicalutamid\u0103 este o combina\u021bie comun\u0103. Blocajul androgen maximal are un beneficiu de supravie\u021buire modest fa\u021b\u0103 de LHRH singur.<\/p>\n<h3>S\u0103n\u0103tatea osului?<\/h3>\n<p>Privarea androgen\u0103 pe termen lung accelereaz\u0103 pierderea osoas\u0103. Ad\u0103uga\u021bi un bifosfonat (acid zoledronic) sau denosumab \u00een osteopenie\/osteoporoz\u0103. Suplimentare cu calciu \u0219i vitamina D.<\/p>\n<h3>Sarcin\u0103?<\/h3>\n<p>Antiandrogenii sunt teratogeni \u2014 partenerii trebuie s\u0103 foloseasc\u0103 contracep\u021bie eficient\u0103 \u00een timpul terapiei. Cel mai relevant pentru b\u0103rba\u021bii mai tineri cu boal\u0103 localizat\u0103.<\/p>\n<h3>Ce fac dac\u0103 uit o doz\u0103?<\/h3>\n<p>Lua\u021bi c\u00e2nd v\u0103 aminti\u021bi dac\u0103 este aceea\u0219i zi; altfel omite\u021bi. Specialistul poate avea indica\u021bii specifice pentru dozele ratate \u00een func\u021bie de regim.<\/p>\n<h3>Monitorizare cardiovascular\u0103?<\/h3>\n<p>Obligatorie pentru fosfestrol; recomandat\u0103 pentru abirateron (TA, reten\u021bie de lichide, electroli\u021bi); de rutin\u0103 pentru bicalutamid\u0103 (evaluare CV ocazional\u0103).<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h2>Alte Terapii Anticanceroase \u0219i Antiandrogene<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/calutide\/\">Calutide<\/a> \u2014 bicalutamid\u0103 50 mg \u2014 marc\u0103 alternativ\u0103 de antiandrogen<\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/xbira\/\">Xbira<\/a> \u2014 abirateron 250 mg \u2014 inhibitor CYP17 pentru mCRPC<\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/honvan\/\">Honvan<\/a> \u2014 fosfestrol 120 mg \u2014 difosfat de dietilstilbestrol<\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/estramustine\/\">Estramustin\u0103<\/a> \u2014 fosfat de estramustin\u0103 \u2014 agent alchilant pentru boala hormonal-refractar\u0103<\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/zoldria\/\">Zoldria<\/a> \u2014 acid zoledronic IV pentru metastaze osoase<\/li>\n<\/ul>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:12px 16px;margin:18px 0;border-radius:3px;font-size:.95em;\"><strong>Disclaimer medical:<\/strong> Tratamentul cancerului este foarte individualizat. Medicamentul specific, doza, programul, monitorizarea \u0219i \u00eengrijirea de sus\u021binere trebuie stabilite de un oncolog sau hematolog calificat, pe baza biologiei tumorii, stadializ\u0103rii, comorbidit\u0103\u021bilor \u0219i obiectivelor terapiei. Aceast\u0103 informa\u021bie are caracter educa\u021bional; nu \u00eenlocuie\u0219te sfatul medical profesionist.<\/div>","protected":false},"excerpt":{"rendered":"<p>Honvan (Fosfestrol 120 mg) \u2014 estrogen de doz\u0103 mare din difosfat de dietilstilbestrol pentru cancerul de prostat\u0103 metastatic avansat. Riscuri cardiovasculare \u0219i trombotice semnificative.<\/p>","protected":false},"featured_media":53311,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3595,3141,3223],"product_tag":[],"class_list":{"0":"post-53310","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-anti-cancer-medication","7":"product_cat-category-overview","8":"product_cat-chronic-conditions","10":"first","11":"outofstock","12":"shipping-taxable","13":"purchasable","14":"product-type-variable","15":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product\/53310","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/comments?post=53310"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media\/53311"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media?parent=53310"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_brand?post=53310"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat?post=53310"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_tag?post=53310"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}